Development of HEMATIN (cas 15489-90-4) conjugated PLGA nanoparticle for selective cancer targeting

Add time:08/24/2019    Source:sciencedirect.com

Targeted nanomedicine for cancer therapy has gained widespread popularity and is being extensively explored. Porphyrins have intrinsic tumor localizing ability and have been studied for photodynamic therapy. However, they have not been used as cancer targeting agents for nanomedicines. In this study, PLGA nanoparticles were formulated and an iron-containing blood porphyrin, HEMATIN (cas 15489-90-4) was conjugated to the surface of the nanoparticles to investigate selectivity towards cancer cell and cellular internalization. Hematin was previously shown to facilitate growth and proliferation of cancer cells. PLGA nanoparticles were characterized by FE-SEM, AFM, DLS, and Zeta potential analyzer. The conjugation of hematin was confirmed by FTIR. HeLa cells were used to study tumor selectivity and uptake. Hematin conjugated particles (ζ potential: − 15.19 mV) showed higher affinity towards the cancer cells than the control particles. The result indicated that the particles were internalized by heme carrier protein-1. Together these data suggest that hematin is a promising cancer targeting material for nanotherapeutics.

We also recommend Trading Suppliers and Manufacturers of HEMATIN (cas 15489-90-4). Pls Click Website Link as below: cas 15489-90-4 suppliers

Prev:Inner filter with carbon quantum dots: A selective sensing platform for detection of HEMATIN (cas 15489-90-4) in human red cells
Next:Novel carbazole aminoalcohols as inhibitors of β-HEMATIN (cas 15489-90-4) formation: Antiplasmodial and antischistosomal activities)